Insulet (PODD) AI Stock Analysis

• Market Cap: $22.54B
• Dividend Yield: N/A
• Average Volume (3M): 524.46K
• Price to Earnings (P/E): 97.5
• Beta (1Y): 0.97
• Revenue Growth: 25.99%
• EPS Growth: -40.46%
• Country: US
• Employees: 3,900
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 1.17
• Shares Outstanding: 70,392,530
• 10 Day Avg. Volume: 430,720
• 30 Day Avg. Volume: 524,456
• PEG Ratio: 0.43
• Price to Book (P/B): 15.10
• Price to Sales (P/S): 8.83
• P/FCF Ratio: 59.90
• Enterprise Value/Market Cap: 1.00
• Enterprise Value/Revenue: 9.53
• Enterprise Value/Gross Profit: 13.47
• Enterprise Value/Ebitda: 55.23
• 1Y Price Target: $368.50
• Price Target Upside: 15.06% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 18
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 71 Outperform
• Price Target: $349.00 ▲(8.97% Upside)

Insulet's strong financial performance and positive earnings call sentiment are the most significant factors driving the stock score. The robust revenue growth and raised guidance provide a positive outlook. However, the high P/E ratio and lack of dividend yield weigh down the valuation score, while technical indicators suggest a neutral trend.

Positive Factors

Revenue Growth

The significant year-over-year revenue growth indicates strong market demand and successful product adoption, reinforcing Insulet's market position and supporting long-term business expansion.

International Market Expansion

Robust international growth reflects successful global market penetration and diversification, enhancing revenue stability and reducing dependence on the U.S. market.

Product Innovation

Continued innovation in product offerings, such as the Omnipod 5, strengthens Insulet's competitive edge and supports sustained growth in the diabetes management market.

Negative Factors

Net Profit Margin Decline

A decline in net profit margin could indicate rising costs or pricing pressures, potentially affecting profitability and financial health if not addressed.

Inventory-Related Charges

Inventory charges can signal inefficiencies or demand forecasting issues, which may impact margins and operational effectiveness if persistent.

Potential Medicare Impact

Potential regulatory changes in Medicare could affect reimbursement rates and market dynamics, posing a risk to revenue stability and growth in the healthcare sector.

Insulet Business Overview & Revenue Model

Company Description

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

How the Company Makes Money

Insulet generates revenue primarily through the sale of its Omnipod Insulin Management Systems and the related consumable products, such as insulin cartridges and infusion sets. The company has a subscription-based model for the consumables, which provides a recurring revenue stream as patients require ongoing supplies for their insulin delivery. Additionally, partnerships with healthcare providers and payers enhance its revenue model, as Insulet collaborates with insurance companies to ensure coverage for its products, thereby increasing accessibility for users. The company also invests in research and development to enhance its products, potentially leading to new revenue opportunities through innovation and improved technology integration with diabetes management solutions.

Insulet Financial Statement Overview

Summary

Insulet's financial performance is robust, with strong revenue growth and profitability metrics. The company has improved its leverage position and continues to generate healthy cash flows. While there is a slight decline in net profit margin, the overall financial health remains strong, positioning the company well in the medical devices industry.

Income Statement

Insulet has demonstrated strong revenue growth with a 7.3% increase in TTM, supported by a robust gross profit margin of 70.7%. The net profit margin has slightly decreased to 10% from the previous annual report's 20.2%, indicating some pressure on profitability. However, the EBIT and EBITDA margins remain healthy, reflecting efficient operations.

Balance Sheet

The company's debt-to-equity ratio has improved to 0.96 in TTM, showing reduced leverage compared to previous periods. Return on equity is strong at 18.4%, indicating effective use of equity to generate profits. The equity ratio stands at 42.2%, suggesting a balanced capital structure with a solid equity base.

Cash Flow

Insulet's free cash flow growth is impressive at 35% in TTM, indicating strong cash generation capabilities. The operating cash flow to net income ratio is 0.50, showing moderate cash conversion efficiency. The free cash flow to net income ratio of 0.78 suggests a healthy cash flow relative to net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.36B	2.07B	1.70B	1.31B	1.10B	904.40M
Gross Profit	1.67B	1.45B	1.16B	805.60M	752.10M	582.30M
EBITDA	407.30M	423.70M	323.60M	109.00M	139.60M	110.30M
Net Income	236.10M	418.30M	206.30M	4.60M	16.80M	6.80M
Balance Sheet
Total Assets	3.47B	3.09B	2.59B	2.25B	2.05B	1.87B
Cash, Cash Equivalents and Short-Term Investments	1.12B	953.40M	704.20M	674.70M	791.60M	947.60M
Total Debt	1.42B	1.42B	1.45B	1.43B	1.29B	1.08B
Total Liabilities	2.01B	1.88B	1.86B	1.77B	1.49B	1.27B
Stockholders Equity	1.46B	1.21B	732.70M	476.40M	556.30M	603.60M
Cash Flow
Free Cash Flow	388.30M	305.40M	70.10M	-38.30M	-190.80M	-82.50M
Operating Cash Flow	506.50M	430.30M	145.70M	119.00M	-68.10M	84.00M
Investing Cash Flow	-136.20M	-146.20M	-119.40M	-191.10M	-82.70M	14.00M
Financing Cash Flow	-78.90M	-28.10M	-13.60M	-40.30M	40.70M	605.50M

Insulet Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 320.27
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PODD, the sentiment is Positive. The current price of 320.27 is above the 20-day moving average (MA) of 319.52, below the 50-day MA of 325.99, and above the 200-day MA of 295.90, indicating a neutral trend. The MACD of -0.86 indicates Positive momentum. The RSI at 50.24 is Neutral, neither overbought nor oversold. The STOCH value of 34.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PODD.

Insulet Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ZBH	75 Outperform	$20.44B	25.13	6.52%	0.93%	4.11%	-14.43%
STE	73 Outperform	$23.82B	36.67	9.73%	0.99%	2.47%	63.68%
PODD	71 Outperform	$22.54B	97.47	19.18%	―	25.99%	-40.46%
DXCM	69 Neutral	$23.86B	34.05	30.63%	―	14.21%	5.66%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PHG	50 Neutral	$26.80B	-34.32	―	3.16%	-0.76%	-55.03%
TNDM	46 Neutral	$1.03B	―	-111.91%	―	25.84%	-47.67%

Insulet Corporate Events

Insulet’s New Study on Simplified Onboarding for Type 2 Diabetes Management: A Potential Game Changer

Insulet Corporation is currently conducting a study titled ‘Feasibility of Simplified Onboarding in Adults With Type 2 Diabetes Using Automated Insulin Delivery.’ The study aims to evaluate the safety and tolerability of different starting doses of insulin in adults with type 2 diabetes using the Omnipod M System, which includes an Omnipod M Pod, an Omnipod M Controller, and a Dexcom G6 continuous glucose monitoring sensor. This study is significant as it seeks to simplify the onboarding process for diabetes management, potentially improving patient outcomes.

Insulet’s Omnipod 5 Study: A Real-World Evaluation of Diabetes Management

Insulet Corporation has announced a new clinical study titled ‘Omnipod 5 – A French Prospective Multicentric Study in Real World.’ The study aims to assess the effectiveness of the Omnipod 5 Automated Insulin Delivery System in managing glycemic control, enhancing quality of life, and reducing diabetes complications for Type 1 diabetes patients. This research is significant as it evaluates the system’s performance in real-world settings, providing valuable insights into patient satisfaction and experience.

Insulet’s Omnipod 5 SA2.0 Study: A Leap in Diabetes Management

Insulet Corporation is conducting a clinical study titled ‘Safety and Effectiveness of the Omnipod® 5 SmartAdjust 2.0 System in Individuals With Type 1 and Type 2 Diabetes.’ The primary goal is to assess the safety and effectiveness of the Omnipod 5 SmartAdjust 2.0 System for individuals aged 2-70 with diabetes, a significant step in diabetes management technology.

Insulet’s Omnipod 5 Study: A Real-World Evaluation of Diabetes Management

Insulet Corporation has launched a post-market registry study titled ‘Post Market Registry to Collect Real-World Safety and Effectiveness Data for the Omnipod 5 System in Children and Adults With Type 1 Diabetes.’ The study aims to gather real-world evidence on the safety and effectiveness of the Omnipod 5 System, a device designed to manage Type 1 Diabetes in both children and adults. This study is significant as it seeks to provide comprehensive data on the system’s performance in everyday settings.

Insulet Appoints Robbie Huffines as New Director

On October 21, 2025, Insulet Corporation appointed Robbie Huffines as a Class II director, effective October 31, 2025. Huffines, a former Global Chair of Investment Banking at JP Morgan Chase, brings extensive experience in healthcare investment banking to Insulet’s Board and will serve on its Audit Committee. This strategic appointment is expected to bolster Insulet’s growth and enhance shareholder value, as Huffines’ expertise aligns with the company’s mission of innovation and improving diabetes care.

The most recent analyst rating on (PODD) stock is a Buy with a $370.00 price target. To see the full list of analyst forecasts on Insulet stock, see the PODD Stock Forecast page.

Insulet Appoints New CFO Amid Revenue Growth

On September 16, 2025, Insulet Corporation announced the appointment of Flavia Pease as the new Chief Financial Officer, succeeding Ana Maria Chadwick. This transition is expected to ensure continued financial stability and growth, as Pease brings extensive experience from her previous roles at Charles River Laboratories and Johnson & Johnson. Additionally, Insulet anticipates exceeding its third-quarter 2025 revenue growth guidance, driven by strong new customer starts in both U.S. and international markets, which reflects positively on its market performance and future outlook.

The most recent analyst rating on (PODD) stock is a Buy with a $365.00 price target. To see the full list of analyst forecasts on Insulet stock, see the PODD Stock Forecast page.

Insulet Corporation Reports Strong Q2 2025 Growth

Insulet Corporation, based in Massachusetts, is a leading medical device company specializing in tubeless insulin pump technology through its Omnipod product platform, offering innovative solutions for diabetes management.

Insulet’s Earnings Call Highlights Robust Growth and Optimism

Insulet Corporation’s recent earnings call conveyed a predominantly positive sentiment, underscored by remarkable revenue growth and successful international expansion. The company demonstrated confidence in its future by raising its full-year guidance, despite facing some financial challenges such as inventory-related charges and increased interest expenses. Overall, the positive developments significantly outweighed the negatives, painting a promising picture for Insulet’s future.